Hypothesis: daptomycin permeabilizes membranes by forming self assembled nanotubes

Daptomycin is the only lipopeptide antibiotic that is widely used in clinical practice. It was discovered by Eli Lilly and then studied and commercialized by Cubist Pharmaceuticals in 2003. Although this antibiotic has been used for 17 years, the debate over its mechanism of action is ongoing. In th...

Full description

Bibliographic Details
Main Author: Alexander Zhivich
Format: Article
Language:English
Published: Doctrine 2020-11-01
Series:Microbiology Independent Research Journal
Online Access:https://www.scienceopen.com/hosted-document?doi=10.18527/2500-2236-2020-7-1-59-71
_version_ 1797221085712744448
author Alexander Zhivich
author_facet Alexander Zhivich
author_sort Alexander Zhivich
collection DOAJ
description Daptomycin is the only lipopeptide antibiotic that is widely used in clinical practice. It was discovered by Eli Lilly and then studied and commercialized by Cubist Pharmaceuticals in 2003. Although this antibiotic has been used for 17 years, the debate over its mechanism of action is ongoing. In this paper, we discuss the different hypotheses on the mode of action of this antibiotic with a primary focus on the bacterial membrane permeabilization as the main mechanism of action. By comparing the experimental data on the oligomerization of daptomycin in membranes with properties of self-assembling cyclic peptides, we conclude that the structure of daptomycin oligomer should resemble the structures of peptide nanotubes that serve as ion channels in membranes.
first_indexed 2024-03-11T07:16:46Z
format Article
id doaj.art-8e5897ea173842c7a3bc97036e874620
institution Directory Open Access Journal
issn 2500-2236
language English
last_indexed 2024-04-24T12:59:50Z
publishDate 2020-11-01
publisher Doctrine
record_format Article
series Microbiology Independent Research Journal
spelling doaj.art-8e5897ea173842c7a3bc97036e8746202024-04-05T16:00:20ZengDoctrineMicrobiology Independent Research Journal2500-22362020-11-0171597110.18527/2500-2236-2020-7-1-59-71Hypothesis: daptomycin permeabilizes membranes by forming self assembled nanotubesAlexander ZhivichDaptomycin is the only lipopeptide antibiotic that is widely used in clinical practice. It was discovered by Eli Lilly and then studied and commercialized by Cubist Pharmaceuticals in 2003. Although this antibiotic has been used for 17 years, the debate over its mechanism of action is ongoing. In this paper, we discuss the different hypotheses on the mode of action of this antibiotic with a primary focus on the bacterial membrane permeabilization as the main mechanism of action. By comparing the experimental data on the oligomerization of daptomycin in membranes with properties of self-assembling cyclic peptides, we conclude that the structure of daptomycin oligomer should resemble the structures of peptide nanotubes that serve as ion channels in membranes.https://www.scienceopen.com/hosted-document?doi=10.18527/2500-2236-2020-7-1-59-71
spellingShingle Alexander Zhivich
Hypothesis: daptomycin permeabilizes membranes by forming self assembled nanotubes
Microbiology Independent Research Journal
title Hypothesis: daptomycin permeabilizes membranes by forming self assembled nanotubes
title_full Hypothesis: daptomycin permeabilizes membranes by forming self assembled nanotubes
title_fullStr Hypothesis: daptomycin permeabilizes membranes by forming self assembled nanotubes
title_full_unstemmed Hypothesis: daptomycin permeabilizes membranes by forming self assembled nanotubes
title_short Hypothesis: daptomycin permeabilizes membranes by forming self assembled nanotubes
title_sort hypothesis daptomycin permeabilizes membranes by forming self assembled nanotubes
url https://www.scienceopen.com/hosted-document?doi=10.18527/2500-2236-2020-7-1-59-71
work_keys_str_mv AT alexanderzhivich hypothesisdaptomycinpermeabilizesmembranesbyformingselfassemblednanotubes